Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company specializing in AI-Immunology™-powered vaccines, has announced the expansion of its proprietary AI-Immunology™ platform into the development of treatments for autoimmune diseases. This strategic move marks a significant step forward, positioning Evaxion to target three core disease areas: cancer, infectious diseases, and now autoimmune disorders. The company’s CEO, Helen Tayton-Martin, emphasized the high unmet medical need in autoimmune conditions, which can be severely debilitating or even life-threatening, placing a major burden on patients and healthcare systems. She highlighted that the AI-Immunology™ platform offers a unique ability to decode the human immune system and identify precision treatment targets—addressing root disease mechanisms rather than just symptoms, as is common with current therapies. Evaxion plans to expand and retrain its AI-Immunology™ platform for autoimmune applications during the second half of 2026. The work is already factored into the company’s financial planning and will not impact its current cash runway, which is expected to extend into the second half of 2027. This expansion is one of several key milestones the company has set for 2026, reflecting its strategy to generate value from both its platform and pipeline through strategic partnerships. Other 2026 targets include gathering additional biomarker and immunogenicity data for its lead candidate EVX-01, advancing the platform’s application in autoimmune diseases, delivering three-year phase 2 clinical efficacy data for EVX-01, filing regulatory documentation for the phase 1 trial of EVX-04, and completing design and preclinical validation of antigens for EVX-B4. Evaxion’s AI-Immunology™ platform uses advanced artificial intelligence to predict immune responses and accelerate the discovery of novel immunotherapies. The company currently has a clinical-stage oncology pipeline of personalized cancer vaccines and a preclinical pipeline focused on bacterial and viral infections with significant unmet needs. The expansion into autoimmune diseases is expected to enhance the depth and breadth of Evaxion’s pipeline, increasing the number of potential programs available for future partnerships. The company remains committed to leveraging its AI-driven platform to deliver innovative, targeted therapies that improve patient outcomes. For more information about Evaxion and its AI-Immunology™ platform, visit the company’s website. Forward-looking statements in this announcement are subject to risks and uncertainties, including those related to development timelines, clinical trial results, regulatory approvals, funding, partnerships, and broader economic and geopolitical factors. These risks are detailed in Evaxion’s filings with the U.S. Securities and Exchange Commission.